Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants
暂无分享,去创建一个
I. Melero | G. González-Aseguinolaza | S. Hervás-Stubbs | J. Lasarte | M. Rodríguez | N. Casares | J. Pardo | M. Hommel | Enric Vercher | U. Mancheño | E. Elizalde | E. Conde | Gorka Alkorta | Iratxe Uranga-Murillo | Javier Glez-Vaz | Estefania Rodriguez-Garcia | Marta Soria-Castellano | Jesús Suarez-Olmos
[1] M. Maus,et al. Mechanisms of response and resistance to CAR T cell therapies. , 2021, Current opinion in immunology.
[2] M. Maus,et al. Recent advances and discoveries in the mechanisms and functions of CAR T cells , 2021, Nature Reviews Cancer.
[3] J. Serody,et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer , 2020, The Journal of experimental medicine.
[4] Lingling Wu,et al. cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy , 2020, Science Translational Medicine.
[5] J. Trapani,et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity , 2020, Nature Immunology.
[6] D. Sancho,et al. Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens , 2020, Journal for ImmunoTherapy of Cancer.
[7] I. Melero,et al. Cellular cytotoxicity is a form of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.
[8] W. See,et al. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading , 2019, Cancer Immunology Research.
[9] I. Melero,et al. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. , 2019, Cancer cell.
[10] F. Supek,et al. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy , 2019, Nature Genetics.
[11] P. Desprès,et al. Ayapana triplinervis Essential Oil and Its Main Component Thymohydroquinone Dimethyl Ether Inhibit Zika Virus at Doses Devoid of Toxicity in Zebrafish , 2019, Molecules.
[12] S. Darko,et al. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Luke,et al. STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.
[14] H. Heslop,et al. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR , 2019, Cancer Immunology Research.
[15] M. Sadelain,et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.
[16] Nan Yan,et al. STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death , 2019, The Journal of experimental medicine.
[17] K. Ishii,et al. Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function , 2019, Life Science Alliance.
[18] Kristy M Ainslie,et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. , 2018, JCI insight.
[19] Hiroki Tanaka,et al. Hyaluronidase inhibits reactive adipogenesis and inflammation of colon and skin. , 2018, JCI insight.
[20] C. Mackall,et al. Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.
[21] S. Dougan,et al. Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial. , 2018, Gastroenterology.
[22] F. Voltarelli,et al. Syngeneic B16F10 Melanoma Causes Cachexia and Impaired Skeletal Muscle Strength and Locomotor Activity in Mice , 2017, Front. Physiol..
[23] A. Villunger,et al. Signalling strength determines proapoptotic functions of STING , 2017, Nature Communications.
[24] K. Mansfield,et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.
[25] M. Sorokin,et al. Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death , 2017, The Journal of Immunology.
[26] T. Gajewski,et al. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.
[27] J. Wolchok,et al. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Kaisho,et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.
[29] J. D. Del Valle,et al. Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. , 2016, Cancer research.
[30] Julián Pardo,et al. How Do Cytotoxic Lymphocytes Kill Cancer Cells? , 2015, Clinical Cancer Research.
[31] George E. Katibah,et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.
[32] Peng Qiu,et al. Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells , 2015, Cancer Immunology Research.
[33] T. Naoe,et al. Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells , 2015, The Journal of Immunology.
[34] B. Luikart,et al. Hyperactivity of Newborn Pten Knock-out Neurons Results from Increased Excitatory Synaptic Drive , 2015, The Journal of Neuroscience.
[35] Ying Wang,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.
[36] Sebastian Amigorena,et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.
[37] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[38] S. Rosenberg,et al. EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss , 2013, Clinical Cancer Research.
[39] Mikala Egeblad,et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.
[40] K. Murphy,et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.
[41] G. Scagliotti,et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[43] K. Murphy,et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells , 2010, The Journal of experimental medicine.
[44] S. Miller,et al. Epitope spreading in immune-mediated diseases: implications for immunotherapy , 2002, Nature Reviews Immunology.
[45] A. Houghton,et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[46] P. Erb,et al. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. , 1994, Journal of immunology.
[47] W. Silvers,et al. "Intrinsic" Immunological Tolerance in Allophenic Mice , 1967, Science.
[48] E. Gilboa,et al. Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.